Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

[cafead]

via Novartis has announced positive data from a Phase III trial investigating iptacopan in patients with paroxysmal nocturnal haemoglobinuria (PNH). The study met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints.

article source